Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    Date published:

  • Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population

    Date published:

  • Canagliflozin and Cardiovascular Outcomes in Patients With and Without Peripheral Artery Disease At Baseline: Data from the CANVAS Program and CREDENCE Trials

    Heart, Lung and Circulation Date published:

  • SSaSS - The China salt substitute and stroke study

    Open Science Framework Date published:

  • Projected effects on salt purchases following implementation of a national salt reduction policy in South Africa

    Public Health Nutrition Date published:

  • Influence of sugar label formats on consumer understanding and amount of sugar in food choices: a systematic review and meta-analyses

    Nutrition Reviews Date published:

  • Feasibility and validity of using death surveillance data and SmartVA for fact and cause of death in clinical trials in rural China: a substudy of the China salt substitute and stroke study (SSaSS)

    Journal of Epidemiology and Community Health Date published:

  • Correction to: Contribution of major food companies and their products to household dietary sodium purchases in Australia

    International Journal of Behavioral Nutrition and Physical Activity Date published:

  • Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019

    Journal of the American College of Cardiology Date published:

  • The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

    International Journal of Cardiology Date published:

  • The impact of voluntary front-of-pack nutrition labelling on packaged food reformulation: A difference-in-differences analysis of the Australasian Health Star Rating scheme

    PLOS Medicine Date published:

  • Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2

    Clinical Journal of the American Society of Nephrology Date published:

  • Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study

    Diabetes Care Date published:

  • Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

    The Lancet Diabetes & Endocrinology Date published:

  • Drawing on Strategic Management Approaches to Inform Nutrition Policy Design: An Applied Policy Analysis for Salt Reduction in Packaged Foods

    International Journal of Health Policy and Management Date published:

  • Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide

    Journal of the American College of Cardiology Date published: